基本信息

职称 副主任医师

职务 福建医科大学肿瘤临床医学院放射医学教研组秘书

研究方向 肿瘤放疗与化学材料结合的医工交叉学科研究

电子邮件 xuyuanji@fjmu.edu.cn

个人简介

许元基，男，福建省肿瘤医院胸部肿瘤放疗科副主任医师，肿瘤学博士,福州大学博士后，硕士生导师，福建省高层次人才（C类），入选福建省肿瘤医院第一批“高层次人才（第四层次）”、“优秀青年人才”计划。本科毕业于西南医科大学，硕士和博士毕业于福建医科大学。2022年3月-8月于复旦大学附属肿瘤医院放疗科进修半年，2022年12月至2023年12月在加拿大英属哥伦比亚大学BC癌症研究中心访学一年。申请人一直从事胸部肿瘤放疗的临床与基础研究，特别是近年来致力于肿瘤放疗与化学材料结合的医工交叉学科研究。近5年主持国家自然科学基金面上项目、福建省自然科学基金等课题6项，作为骨干成员参与2项国自然区域联合基金重点项目。迄今，以通讯/第一作者身份在Nano Today，Analytical Chemistry及Cancer Letters等国际期刊上发表22篇SCI，其中中科院一区、二区SCI文章8篇，一篇影响因子最高达13.2分。曾任Frontiers in Genetics杂志食管癌基础研究专栏客座主编，《中华肿瘤防治杂志》第九届编委会青年编委。获2024年福建省抗癌协会科技进步二等奖（第一完成人）；福建省肿瘤医院第三届“星火奖”；福建省肿瘤医院2023年度科研先进工作者、中青年个人成长奖；第二十三届、二十四届福建省肿瘤学术大会优秀论文奖。担任福建省核学会第三届放射肿瘤治疗学分会委员、福建省医学会放射治疗学分会第四届青委会委员、福建省抗癌协会第一届纵隔肿瘤专委会委员等职务。

主要科研项目

1、国家自然科学基金委员会,面上项目, 82373101,化学和生物协同放疗增敏诊疗分子的构筑及在肿瘤精准成像与治疗中的应用研究, 2024-01-01至2027-12-31, 49万元,在研,主持;

2、福建省肿瘤医院,第一批高层次人才（第四层次）培养项目,新型生物响应放疗增敏剂在肿瘤疗效早评价中的应用研究, 2022YNG-11, 2023-01至2027-12, 100万,在研,主持;

3、福建省科技厅,福建省自然科学面上项目, 2023J01178,去泛素化酶USP13抑制SASS6蛋白泛素化降解促进食管鳞癌细胞增殖的机制研究,2023-07至2026-07, 10万元,在研,主持

4、国家自然科学基金委员会,联合基金项目, U22A20326, NFE2L2-cGAS-STING信号通路在中国人食管鳞癌放疗和免疫治疗中的作用机制研究, 2023-01-01至2026-12-31, 255万元,在研,参与

5、国家自然科学基金委员会,联合基金项目, U21A20377,新型肿瘤放疗增敏及疗效实时成像评估体系的构建及应用研究, 2022-01-01至2025-12-31, 260万元,在研,参与

6、福建省肿瘤医院,第一批优秀青年人才培养项目,环状RNA circRNAs在鼻咽癌发生发展中的作用机制研究, 2020YNYQ02, 2021-01至2023-12, 15万,已结题,主持;

7、福建省科技厅,福建省科技创新联合资金项目, 2019Y9034, lncRNA NCAT1通过调控EBV miR-BART13的加工成熟促进鼻咽癌转移的功能和机制研究, 2020-09至2023-09, 15万元,已结题,主持

8、福建省科技厅,福建省自然科学基金青创项目, 2019J05140, EB病毒miR-BART13通过NKIRAS2介导鼻咽癌侵袭转移的分子机制研究, 2019-07至2022-07, 3万元,已结题,主持

9、福建省卫生健康委员会，福建省卫生健康中青年骨干人才培养项目, 2019-ZQN-14, EB病毒miR-BART13促进鼻咽癌细胞免疫逃逸的机制研究, 2019-09至2022-08, 8万元,已结题,主持

10、福建医科大学，福建医科大学启航基金项目，2018QH1222，EB病毒miR-BART13通过靶向调控NKIRAS2促进鼻咽癌增殖的分子机制研究, 2018-12至2021-12，5万元，已结题，主持

获奖经历

1、许元基(1/8);食管癌的分子标志物特征及个体化精准放疗的临床研究,福建省抗癌协会,科技进步二等奖,其他, 2024(许元基;陈元美;林智忠;沈永师;林宇;李建成;陈明秋;陈俊强)（科研奖励）

近五年发表的主要论文（第一作者^#，通讯作者^*）

1.Xu LY^#, Chen YM^#, Ye JQ, Fan M, Weng GB, Shen YS, Lin ZZ, Lin D^*,Xu YJ^*,Feng SY^*. Optical Nanobiosensor Based on Surface-Enhanced Raman Spectroscopy and Catalytic Hairpin Assembly for Early-Stage Lung Cancer Detection via Blood Circular RNA.ACS Sens,2024, 9(4): 2020-2030. (中科院一区,IF=8.9)

2.Chen KB，Lin ZZ，Shen YS，Lin YJ，Chen JH，Eslick GD，Chen YM，Xu YJ^*，Xin Y^*. A novel amino acid metabolism-related gene signature to predict the overall survival of esophageal squamous cell carcinoma patients.J Thorac Dis,2024, 16(6)：3967-3989.（中科院三区，IF=2.1）

3.Su LC^#, Tang HD^#, Lian NS, Chen ZX^*, Li H, Ge XG, Wu Y, Li QQ, Zhang X, Chen JQ^*, Song JB^*,Xu YJ^*. Spatiotemporally Confined Assembly of Radiosensitizers for Synergistic Radio-Chemodynamic Therapy on Deep Tumor of Rabbit.Nano Today, 2023, 50: 101835. (中科院一区,IF=13.2)

4.Yuan M, Fang X, Wu Y,Xu YJ^*, Feng HJ, Mu J^*, Chen ZX, Lin YH, Fu QR, Du W, Yang HH, Song JB^*. Activatable Nanoprobe with Aggregation-Induced Dual Fluorescence and Photoacoustic Signal Enhancement for Tumor Precision Imaging and Radiotherapy.Anal Chem,2022,94:5204-5211.(中科院一区,IF=7.4)

5.Xu YJ^#, Zhou R^#, Zong JF, Lin WS, Tong S, Guo QJ, Lin C, Lin SJ, Chen YX, Chen MR, Chen HL, Ye YB^*, Pan JJ^*. Epstein-Barr virus-coded miR-BART13 promotes nasopharyngeal carcinoma cell growth and metastasis via targeting of the NKIRAS2/NF-κB pathway.Cancer Lett, 2019, 447: 33-40. (中科院一区, IF=7.36)

6.Xu YJ^#, Zhu KS^#, Chen JQ^#, Lin LY, Huang ZR, Zhang JL, Chen YM^*. SASS6 promotes proliferation of esophageal squamous carcinoma cells by inhibiting the p53 signaling pathway.Carcinogenesis,2021, 42(2): 254-262. (中科院二区,IF=4.741)

7.Wang HM^#, Zhang YP^#, Chen L^#, Liu YF^#, Xu C, Jiang DX, Song Q, Wang HX, Wang LY, Lin Y, Chen YM, Chen JQ,Xu YJ^*, Hou YY^*. Identification of clinical prognostic features of esophageal cancer based on m6A regulators.Front Immun,2022, 13:950365. (中科院二区，IF=7.3)

8.Chen YM^#, Huang QY^#, Chen JQ^*, Lin Y, Huang XY, Wang QF, Yang Yong, Chen BJ, Ye YL, Zheng BL, Qi R, Chen YS,Xu YJ*. Primary gross tumor volume is prognostic and suggeststreatment in upper esophageal cancer.BMC Cancer,2021, 21:1130. (中科院二区, IF=4.638)

9.Xu YJ^#, Wu ZJ^#, Ye WZ^#, Xiao YP, Zheng W, Chen QY, Bai PG, Lin ZZ, Chen CC^*. Prognostic value of serum uric acid and tumor response to induction chemotherapy in locally advanced nasopharyngeal carcinoma.BMC Caner,2021, 21:519. (中科院二区, IF=4.638)

10.Zhang YP^#, Chen KB^#, Wang LY, Chen JH, Lin ZZ, Chen YM, Chen JQ, Lin Y^*,Xu YJ^*, Peng HY^*. Identification and validation of a prognostic signature of cuproptosis-related genes for esophageal squamous cell carcinoma.Aging (Albany NY),2023, 15(17): 8993-9021. (中科院三区, IF= 3.9)

11.Xu ZY^#, Ke HQ^#, Zheng BL, Lin CY, Zhang YP, Wang LY, Lin Y, Ye YL, Cai LF, You MX, Chen JQ^*,Xu YJ^*. The prognostic significance of nomogram-based pretreatment inflammatory indicators in patients with esophageal squamous cell carcinoma receiving intenstiy-modulated radiotherapy.Cancer Control,2023,30:1-11. (中科院四区, IF=2.60)

12.Lin Y^#, Ye YL^#, Huang QY, Zheng BL, Yang Y, Chen YM^*, Li WG, Ke HQ, Lin CY, Zhang YP, Wang LY, Chen JQ^*,Xu YJ^*. Influence of age as a continuous variable on survival outcomes and treatment options in patients with upper thoracic esophageal carcinoma.J Cancer,2023, 14(7):1039-1048. (中科院三区,IF=3.9)

13.Lin Y^#, Zheng BL^#, Chen JQ, Huang QY, Ye YL, Yang Y, Chen YM, Chen BJ, You MX, Wang QF^*,Xu YJ^*. Development of a prognostic nomogram and risk stratification system for upper thoracic esophageal squamous cell carcinoma.Front Oncol,2023, 13:1059539. (中科院三区,IF=4.7)

14.Chen YM^#, Huang XY^#, Zhu KS^#, Li CK, Peng HY, Chen L, Huang ZR, Zhang YF, Weng GB, Xiao TY, Chen JQ^*,Xu YJ^*. LIMD2 is a prognostic and predictive marker in patients with esophageal cancer based on a ceRNA network Analysis.Front Genet,2021, 12: 774432. (中科院三区,IF=4.772)

15.Lin ZZ, Chen L, Wu TT*, Zhang YP, Huang XY, Chen YM, Chen JQ,Xu YJ*. Prognostic Value of SPOCD1 in Esophageal Squamous Cell Carcinoma: A Comprehensive Study Based on Bioinformatics and Validation.Front Genet,2022,13:872026. (中科院三区,IF=3.7)

16.Huang CB^#, Chen L^#, Zhang YP, Wang LY, Zheng W, Peng FY*,Xu YJ*. Predicting AURKA as a novel therapeutic target for NPC: A comprehensive analysis based on bioinformatics and validation.Front Genet,2022, 13:926546. (中科院三区,IF=3.7)

17.Xu YJ^#, Huang XY^#, Ye WZ, Zhang YF，Li CK，Bai PG，Lin ZZ，Chen CB^*. Comprehensive analysis of key genes in nasopharyngeal carcinoma based on bioinformatics analysis.Cancer Cell Int,2020, 20: 408. (中科院三区，IF=4.175)

18.Xu YJ^#, Wang JL^#, Cai SL, Chen GH, Xiao NY, Fu YJ, Chen Q, Qiu SF^*. PNCK depletion inhibits proliferation and induces apoptosis of human nasopharyngeal carcinoma cells in vitro and in vivo.J Cancer,2019,10(27): 6925- 6932. (中科院三区，IF=3.182)

19.Chen YM^#, Huang XY^#, Chen L, Weng GB, Huang ZR, Zhang YF, Xiao TY, Chen JQ, Zhu KS*,Xu YJ*. Characterization of the Immune Infiltration Landscape and Identification of Prognostic Biomarkers for Esophageal Cancer.Mol Biotechnol,2023,65(3):361-383. (中科院四区, IF=2.86)

20.Xu YJ^#, Chen L^#, Chen YJ, Ye WZ, Huang XY, Ke MY, Ye GD, Lin LC, Dong KM, Lin ZZ, Bai PG, Chen CB*. Prediction of Potential Biomarkers in Early-Stage Nasopharyngeal Carcinoma Based on Platelet RNA Sequencing.Mol Biotechnol,2023, 65(7):1096-1108 . (中科院四区,IF=2.86)

21.Xu YJ^#, Chen XL^#, Zhang MW, Xiao YP, Zong JF,Guo QJ,Qiu SF, Zheng W, Lin SJ, Pan JJ*. Prognostic effect of parotid area lymph node metastases after preliminary diagnostic of nasopharyngeal carcinoma: a propensity score matching study.Cancer Med,2017, 6(10):2213-21. (中科院三区, IF=3.202)

22.Xu YJ^#, Zhang MW^#, Yue QY^#, Zong JF, Lin J, Sun R, Qiu SF, Lin SJ, Pan JJ*. Analysis of rare periparotid recurrence after parotid gland-sparing intensity-modulated radiotherapy for nasopharyngeal carcinoma.Cancer Radiother,2016, 20(5):377-383. (中科院四区, IF=1.014)